UPB · Why this verdict
Why Upstream Bio (UPB) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.7/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Three of five value-trap indicators are active at once — margin compression (operating margin -39.8%), material insider selling, and negative free cash flow — a combination the engine treats as a warning rather than a value opportunity. Bear case | Fewer than 2 of the 5 value-trap signals should remain active over the next 12 months for the value case to strengthen. | →Stable |
| CounterInsider selling here is minor in dollar terms (0.04% of market cap), suggesting the value-trap classification may be overstating the risk from a single small sale. | ||
Revenue growth remains strong at 83% year-over-year, suggesting continued commercial traction even as profitability lags. Growth breakdown | Revenue growth rate should stay above 30% YoY over the next four quarters to confirm the growth trajectory is intact. | →Stable |
| CounterThe growth score carries low confidence (0.33) and rests on a single revenue_growth component, so the reported 83% YoY figure may not persist as comparisons normalize. | ||
The company is burning cash at an extreme rate (free cash flow at -2719% of revenue) and fails the Rule of 40 test at -2636, raising funding and dilution risk. Quality breakdown | Free cash flow burn as a percentage of revenue should narrow materially, and the Rule of 40 score should trend toward positive over the next 12 months. | →Stable |
| CounterAs a clinical-stage biotech, heavy cash burn ahead of a product launch is expected and does not necessarily indicate financial distress if cash runway is adequate. | ||
The stock's overall quality score of 3.5 sits below the engine's 4.0 minimum floor, triggering an exit-position recommendation on fundamental weakness. Engine summary | The quality score should climb back above the 4.0 floor over the next 12 months for the exit call to be reconsidered. | →Stable |
| CounterQuality scoring for early-stage biotech names is structurally penalized by metrics like ROE and ROA that are not meaningful pre-revenue, so the floor breach may overstate fundamental weakness. | ||
Short interest stands at 11% of float alongside a confirmed technical downtrend (below the 200-day moving average with a -8.5%/30d slope), reflecting bearish positioning from both fundamental and technical traders. Key risks | Short interest should fall below 8% and the stock should reclaim its 200-day moving average over the next 12 months to indicate improving sentiment. | →Stable |
| CounterHigh short interest combined with an overbought RSI reading of 77 could also set up a short-covering rally rather than confirm further downside. | ||
Three of five value-trap indicators are active at once — margin compression (operating margin -39.8%), material insider selling, and negative free cash flow — a combination the engine treats as a warning rather than a value opportunity.
→StableBear case
- Expectation
- Fewer than 2 of the 5 value-trap signals should remain active over the next 12 months for the value case to strengthen.
CounterInsider selling here is minor in dollar terms (0.04% of market cap), suggesting the value-trap classification may be overstating the risk from a single small sale.
Revenue growth remains strong at 83% year-over-year, suggesting continued commercial traction even as profitability lags.
→StableGrowth breakdown
- Expectation
- Revenue growth rate should stay above 30% YoY over the next four quarters to confirm the growth trajectory is intact.
CounterThe growth score carries low confidence (0.33) and rests on a single revenue_growth component, so the reported 83% YoY figure may not persist as comparisons normalize.
The company is burning cash at an extreme rate (free cash flow at -2719% of revenue) and fails the Rule of 40 test at -2636, raising funding and dilution risk.
→StableQuality breakdown
- Expectation
- Free cash flow burn as a percentage of revenue should narrow materially, and the Rule of 40 score should trend toward positive over the next 12 months.
CounterAs a clinical-stage biotech, heavy cash burn ahead of a product launch is expected and does not necessarily indicate financial distress if cash runway is adequate.
The stock's overall quality score of 3.5 sits below the engine's 4.0 minimum floor, triggering an exit-position recommendation on fundamental weakness.
→StableEngine summary
- Expectation
- The quality score should climb back above the 4.0 floor over the next 12 months for the exit call to be reconsidered.
CounterQuality scoring for early-stage biotech names is structurally penalized by metrics like ROE and ROA that are not meaningful pre-revenue, so the floor breach may overstate fundamental weakness.
Short interest stands at 11% of float alongside a confirmed technical downtrend (below the 200-day moving average with a -8.5%/30d slope), reflecting bearish positioning from both fundamental and technical traders.
→StableKey risks
- Expectation
- Short interest should fall below 8% and the stock should reclaim its 200-day moving average over the next 12 months to indicate improving sentiment.
CounterHigh short interest combined with an overbought RSI reading of 77 could also set up a short-covering rally rather than confirm further downside.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Upstream Bio shows resilient revenue growth (83% YoY) but is flagged for exit given a quality score below the engine's minimum floor, extreme cash burn, multiple value-trap signals, and elevated short interest against a confirmed technical downtrend.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 7.2 |
| Rule of 40 | 3.0 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -2719% of revenue
- ▸Rule of 40: -2636 (fail)
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 83% YoY
Momentum
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 1.3 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 2.7 |
- ▸Overbought bear rally (RSI 95)
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -8.6%/30d — confirmed downtrend
Sentiment
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 6.8 |
| Price target | 10.0 |
| erm sentiment | 4.2 |
- ▸Light analyst coverage (8.0) — signal dampened
- ▸Analyst upside: 379%
Insider
4.8/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 4.6 |
- ▸Negligible insider selling — $5,203 (0.001% of mkt cap)
Peer rank
6.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 3.9 |
| growth rank | 7.8 |
- ▸Conservative debt levels
Technical
1.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.1 |
| 52w position | 0.0 |
| gap | 6.0 |
Risk (lower is worse)
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.5 |
| days to cover | 4.5 |
| volatility | 0.0 |
| put call | 10.0 |
| max pain risk | 3.0 |
| debt equity | 10.0 |
- ▸Above max pain $2
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 1.1 |
| earnings timing | 5.0 |
| surprise avg | 0.9 |
- ▸Earnings concerns: 1B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:6.0>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:29d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
- DEATH_CROSS:momentum=6.0>=5.0 recovering
Reward-to-Risk
0.00
Upside
+0.0%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 95
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -76% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Growth at 10.0, Sentiment at 7.1, and Peer rank at 6.4; the weakest are Technical at 1.5, Catalyst at 3.0, and Quality at 3.5. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Revenue Growth Momentum
Trip ifRevenue growth falls below 20% YoY for 2 consecutive quarters.
- P2Cash Burn Runway Risk
Trip ifFree cash flow burn improves to above -1000% of revenue for 2 consecutive quarters.
- P3Quality Floor Breach
Trip ifQuality score rises above 4.0 from the current 3.5.
- P4Value Trap Signal Cluster
Trip ifValue-trap signal count drops below 2 of 5 from the current 3 of 5.
- P5Short Interest Technical Downtrend
Trip ifShort interest falls below 5% of float from the current 11%.